Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 556 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Couple Married For 48 Years Shared A Touching Moment As They... August 22, 2019 Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer May 7, 2021 NHS ‘understaffed and underequipped’ to tackle cancer, say 3 in 4... May 25, 2022 Increased Risk of Haematologic Malignancies Among Children and Adolescents Exposed to... October 7, 2025 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Trastuzumab Deruxtecan Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of... ESMO Asia Congress 2024, Singapore, 6-8 December Cancer in My Community: Reducing Tobacco Use in Tunisia
